Abstract: An optical communication method and system with high spectral efficiency and low power consumption based on joint channel coding modulation relates to the technical field of high-speed fiber communication. The method includes a data acquisition step, a symbol multiplexing joint channel coding modulation step, a signal optical communication step, a channel equalization step, and a symbol demultiplexing step. The optical communication method and system improves the problems of relative independence of forward error correction channel coding (FEC) and high order modulation function modules, long code length dependence of FEC, limited spectral efficiency promotion under the limitation of fiber nonlinear effect, and high FEC decoding latency and power consumption in optical communication system. It is beneficial to improving the spectral efficiency and capacity of a coherent optical communication system and optimizing the system latency and power consumption.

Abstract: The present invention provides novel methods and systems, including cell lines, recombinant polynucleotide constructs, compositions, and kits, for targeted yet universal genomic manipulation.

Abstract: The present invention provides novel methods and systems, including cell lines, recombinant polynucleotide constructs, compositions, and kits, for targeted yet universal genomic manipulation.

Abstract: The present disclosure describes systems and methods for immunotherapies Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell. Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors). The engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.

Abstract: The present invention provides novel methods and systems, including cell lines, recombinant polynucleotide constructs, compositions, and kits, for targeted yet universal genomic manipulation.